Based on our data, the characterization of some genetic regions (CEBPA, CALR, and FLT3) remains a challenge for NGS; this is a major issue, since AML and MPN management strongly depends on their correct detection. This evidence concerns the gene CALR and myeloproliferative neoplasm.